Insider Selling: Omada Health (NASDAQ:OMDA) CFO Sells 1,607 Shares

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 1,607 shares of Omada Health stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.01, for a total transaction of $40,191.07. Following the completion of the transaction, the chief financial officer directly owned 187,209 shares in the company, valued at $4,682,097.09. This represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Omada Health Stock Down 0.7%

NASDAQ:OMDA traded down $0.17 during trading hours on Wednesday, reaching $23.84. 1,552,408 shares of the company’s stock were exchanged, compared to its average volume of 1,274,695. The company has a market capitalization of $1.46 billion, a P/E ratio of 476.80 and a beta of 1.73. The business’s 50-day simple moving average is $20.61 and its two-hundred day simple moving average is $16.32. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a return on equity of 2.67% and a net margin of 1.39%.The company had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. As a group, sell-side analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in OMDA. Quantbot Technologies LP acquired a new stake in shares of Omada Health during the 2nd quarter valued at $1,695,000. Ieq Capital LLC purchased a new stake in shares of Omada Health during the second quarter worth $1,728,000. AlpInvest Partners B.V. acquired a new stake in Omada Health during the second quarter valued at $1,182,000. BlackRock Inc. purchased a new position in Omada Health in the second quarter valued at about $48,775,000. Finally, Deutsche Bank AG acquired a new position in Omada Health in the 2nd quarter worth about $777,000.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
• Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
• Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
• Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Analyst Upgrades and Downgrades

A number of research firms have commented on OMDA. Citigroup reaffirmed an “outperform” rating on shares of Omada Health in a research note on Monday, July 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Omada Health in a research note on Friday, May 8th. Weiss Ratings downgraded shares of Omada Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, July 13th. Citizens Jmp raised their target price on Omada Health from $21.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Monday, July 20th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $24.00 price target on shares of Omada Health in a report on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.75.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.